David Hinkle

About David Hinkle

David Hinkle, age 63, is Senior Vice President, Finance, Controller, and Corporate Treasurer of Boundless Bio (BOLD); he joined in June 2021, was promoted to SVP in June 2023, and was appointed Treasurer, Principal Financial Officer, and Principal Accounting Officer effective October 11, 2024 . He is a CPA (inactive) in California with a B.S. from California State University, Northridge, and previously led finance and controller functions at Crinetics (post-IPO build-out), Ignyta (acquired by Roche), Receptos (acquired by Celgene), Somaxon (acquired by Pernix), and Digirad, indicating deep capital markets and M&A execution experience . Company-level performance metrics (e.g., TSR, revenue/EBITDA growth) and any pay-for-performance linkage specific to Hinkle are not disclosed in the proxy or 10-K; bonus funding for 2024 was set at 90% of target for NEOs based on product and corporate development goals, but individual executive details for Hinkle are not provided .

Past Roles

External Roles

No external public-company directorships or board roles for Hinkle are disclosed in BOLD’s proxy or 10-K .

Fixed Compensation

• Base salary and target bonus % for Hinkle are not disclosed; BOLD’s annual cash bonus program is based on corporate goals and was funded at 90% of target for 2024, with payouts typically determined and paid in Q1 of the following year (individual NEO amounts disclosed; Hinkle not an NEO in 2024) .
• BOLD maintains Nasdaq-compliant clawback policy administered by the Compensation Committee .
• 401(k): company match equal to 25% of the first 4% of eligible contributions, not to exceed 1% of eligible compensation in 2024 .
• Perquisites: company generally does not provide perquisites beyond limited circumstances; executives are eligible for standard health and welfare benefits .

Performance Compensation

Note: Hinkle’s individual performance metrics, weighting, targets, and payout amounts are not disclosed; table reflects company-level design and 2024 funding determination .

Equity Ownership & Alignment

• Beneficial ownership: Hinkle’s share and option holdings are not shown in the 2025 proxy’s security ownership table (which lists directors and 2024 NEOs); therefore, vested/unvested breakdown or ownership as % of outstanding cannot be assessed from filings .
• Hedging and pledging: BOLD prohibits hedging transactions and pledging or margining of company securities; options/derivatives trading is also prohibited under its Insider Trading Compliance Policy .
• Option repricing program: On August 19, 2024, BOLD reduced the exercise price of eligible employee options to $3.56 (closing price on the Repricing Effective Date), with a “Premium End Date” service condition such that early exercise or termination (other than qualifying termination) before the Premium End Date reverts the option to its original exercise price; NEO totals are disclosed, and the repricing applied to eligible employees under the 2018/2024 plans . Whether Hinkle’s awards were repriced is not disclosed by name.
• Clawback: Policy for Recovery of Erroneously Awarded Compensation compliant with Nasdaq/Dodd-Frank .
• Stock ownership guidelines: Not disclosed in the proxy or 10-K.

Employment Terms

• Appointment: Effective October 11, 2024, Hinkle became Treasurer, Principal Financial Officer, and Principal Accounting Officer; he also entered the company’s standard indemnification agreement as of that date .
• Severance and Change-in-Control Severance Plan (company-wide framework):
  • Non-CIC termination (other than for Cause or death/disability) or resignation for Good Reason: Tier-based lump sum base salary (Tier 1: 12 months; Tier 2: 9 months; Tier 3: 6 months), company-paid COBRA for the same duration, and for Tier 1, accelerated vesting of time-based equity that would have vested within 12 months (performance-based awards governed by award terms) .
  • CIC Period (12 months after change in control) with qualifying termination: Tier 1: 18 months base + 1.5x target bonus; Tier 2: 12 months base + 1.0x target bonus; Tier 3: 9 months base + 0.75x target bonus; company-paid COBRA for 18/12/9 months; 100% acceleration of time-based equity; performance-based equity vests at target unless award terms specify otherwise .
  • Definitions (Cause, Good Reason) and required release/ restrictive covenants (non-solicitation, non-disparagement) are detailed in the plan .
  • Hinkle’s specific Tier designation is not disclosed; coverage applies to designated management-level “Covered Employees” .

Investment Implications

• Alignment and selling pressure: Anti-hedging and anti-pledging policies materially reduce misalignment and forced selling risk; combined with the clawback policy, governance posture on alignment is strong .
• Retention risk: The August 2024 option repricing with a Premium End Date service condition is explicitly designed to retain and motivate key contributors without additional dilution or cash comp; while individual inclusion for Hinkle is not disclosed, the program’s structure supports broader retention and may defer near-term exercises at reduced prices until service conditions are met .
• Change-in-control protections: Double-trigger CIC economics with full acceleration of time-based equity and target vesting for performance equity are standard; Tier levels determine magnitude, but Hinkle’s tier is not disclosed. These protections lower transition risk but can raise payout optics if CIC occurs .
• Execution credentials: Hinkle’s prior roles building post-IPO accounting at Crinetics and finance leadership at multiple companies through M&A outcomes (Ignyta, Receptos, Somaxon) suggest capability to scale finance-controls in a newly public, clinical-stage environment—supportive for capital markets readiness and internal controls as PFO .
• Red flags: Company-wide option repricing is a governance sensitivity; BOLD disclosed rationale (retention without incremental dilution/cash) and implemented service conditions to mitigate adverse optics, partially addressing shareholder concerns .